Furthermore, both mechanisms exhibit extensive changes in neoplastic development in different cancer types (14) and loss of GATA3 expression in breast cancer patients has been significantly associated with poor clinical outcome and advanced tumor disease (15). This evidence concerns the gene GATA3 and breast carcinoma.